Leading Products

Aug 11. 2020
(￥ million)

Brand name	Active Ingredient	Indications	Launch Date	Sales 2018	Sales 2019	Sales 2020
Brand name	Active Ingredient	Indications	Launch Date	Sales 2018	Sales 2019	Apr.-Jun.	Apr.-Sep. (estimated)	Annual (estimated)
Vidaza	azacitidine	myelodysplastic syndrome	Mar-2011	14,453	15,652	3,761	8,100	16,800
Zalutia	tadalafil	urinary disorder caused by benign prostatic hyperplasia	Apr-2014	12,118	13,328	3,188	5,000	8,400
Uptravi	selexipag	pulmonary arterial hypertension	Nov-2016	4,825	6,182	1,788	3,700	7,900
Tramal, Onetram	tramadol hydrochloride	cancer pain, chronic pain	Sep-2010	7,196	7,153	1,773	3,600	7,400
Adcirca	tadalafil	pulmonary arterial hypertension	Dec-2009	5,173	5,405	1,468	2,800	5,600
Gazyva	obinutuzumab	CD20-positive follicular lymphoma	Aug-2018	1,417	4,527	1,246	2,700	5,600
Cialis	tadalafil	erectile dysfunction	Jul-2009	4,592	4,472	641	1,700	3,200
Azunol Gargle	sodium gualenate	pharyngitis, tonsillitis, stomatitis, etc.	Aug-2002	2,169	2,159	395	950	2,100
Defitelio	defibrotide sodium	sinusoidal obstruction syndrome	Sep-2019	-	1,071	350	1,000	2,200
Erizas	dexamethasone cipecilate	allergic rhinitis	Dec-2009	2,987	2,387	293	750	2,500
Profit in co-promotion				5,057	5,963	2,184	3,950	8,300
Revenues from the licensing of industrial				16,621	15,860	5,105	8,900	19,700
Pharmaceuticals				100,223	101,643	26,209	52,100	110,700
Functional Food				14,492	14,994	3,703	7,400	15,300
Net Sales				114,716	116,637	29,913	59,500	126,000

Financial Information

About Nippon Shinyaku